Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/6/2025

Dapsone Treatment Guidelines

FDA-Approved Indications

  • The Centers for Disease Control and Prevention recommends leprosy treatment with dapsone at 1-2 mg/kg/day in pediatric patients 1, 2
  • The Centers for Disease Control and Prevention suggests pneumocystis jirovecii pneumonia prophylaxis with dapsone as an alternative to trimethoprim-sulfamethoxazole in HIV-infected adults and children, with a daily dosing of 100 mg showing less than 1% PCP recurrence rate over 16 months for secondary prophylaxis in adults 1, 2, 3, 4, 5, 6
  • The Centers for Disease Control and Prevention recommends weekly dosing of 100-200 mg of dapsone for primary prophylaxis, demonstrating zero failure rate, and 8% recurrence for secondary prophylaxis 1, 2
  • The American Academy of Dermatology notes that dapsone is particularly useful in patients who cannot tolerate TMP-SMX, with approximately 60% of TMP-SMX-intolerant patients able to tolerate dapsone 1, 2
  • The Journal of the American Academy of Dermatology suggests that dapsone provides added prophylactic benefit against PCP in HIV-positive patients with hidradenitis suppurativa requiring systemic antibiotics 7
  • The American Family Physician recommends toxoplasmosis prophylaxis with dapsone when combined with pyrimethamine, providing protection in HIV-infected patients 8, 9

Important Clinical Considerations

  • The Centers for Disease Control and Prevention recommends leprosy treatment in children with 1-2 mg/kg/day divided doses of dapsone 1, 2, 3
  • The Centers for Disease Control and Prevention suggests PCP prophylaxis in adults with 100 mg daily or 100-200 mg weekly of dapsone 1, 2
  • The Centers for Disease Control and Prevention notes that G6PD deficiency screening is mandatory before initiating dapsone therapy due to hemolysis risk, and complete blood count and liver function tests are needed for monitoring due to risks of hemolytic anemia, methemoglobinemia, neutropenia, and hepatotoxicity 10
  • The Centers for Disease Control and Prevention warns of dose-related hemolysis, most common when daily doses exceed 200 mg 1, 2, 3
  • The Journal of the American Academy of Dermatology advises careful consideration of drug interactions in HIV patients when combined with protease inhibitors or other antiretrovirals 7
  • The Centers for Disease Control and Prevention notes that hypersensitivity syndrome ("sulfone syndrome") is a rare but serious reaction characterized by fever, exfoliative dermatitis, hepatic dysfunction, and methemoglobinemia occurring 1-4 weeks into therapy 1, 2, 3

Dapsone Monitoring and Safety

Laboratory Monitoring

  • The Centers for Disease Control and Prevention recommends complete blood count with differential and platelet count at baseline and monthly intervals to assess for hemolytic anemia, methemoglobinemia, and neutropenia 11, 12

Drug Interactions

  • The American Academy of Dermatology notes that rifampin, anticonvulsants, and St. John's wort may affect dapsone levels through acetylation rate changes, and topical benzoyl peroxide can interact with topical dapsone formulations 13

REFERENCES

10

Leprosy Treatment Guidelines [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

13

guidelines of care for the management of acne vulgaris. [LINK]

Journal of the American Academy of Dermatology, 2016